Cardiac Marker Market by Product (Instruments, Reagents & Kits), Biomarker Type (BNP Or NT-ProBNP, CK-MB, Hs-CRP), End-User, Indication - Global Forecast 2024-2030

Cardiac Marker Market by Product (Instruments, Reagents & Kits), Biomarker Type (BNP Or NT-ProBNP, CK-MB, Hs-CRP), End-User, Indication - Global Forecast 2024-2030

The Cardiac Marker Market size was estimated at USD 3.81 billion in 2023 and expected to reach USD 4.16 billion in 2024, at a CAGR 9.71% to reach USD 7.29 billion by 2030.

Cardiac markers are substances or molecules measured in the blood to diagnose and monitor various cardiac conditions, particularly those related to heart muscle damage or stress. These markers are often used in clinical settings, such as hospitals and laboratories, to assist in diagnosing, prognosis, and monitoring cardiovascular diseases. They are particularly widely used in the diagnosis of conditions such as myocardial infarction and other forms of acute coronary syndrome. With an increased emphasis on accurate and early diagnosis in cases of cardiovascular diseases (CVD), the cardiac markers market's valuation has been progressively escalating. The rising incidence of cardiovascular conditions and the growing global geriatric population fuel the market demand for cardiac markers. Rising demand for point-of-care testing and the steady development in healthcare infrastructure, including well-equipped labs and trained personnel, globally aids the industry's growth. However, High prices associated with cardiovascular procedures and solutions affect market adoption. The evolution of the biomedical industry, particularly diagnostic technologies, and government healthcare initiatives and programs aiming to foster preventative care are instrumental in escalating the demand for cardiac markers and creating a significant growth opportunity for the market.

Regional Insights

The Americas has a significant market landscape in the cardiac marker market due to a high prevalence of cardiovascular diseases, well-established healthcare facilities, and major market players. The increasing incidence of heart attacks and the strong focus on early diagnosis and treatment are driving the demand for cardiac marker tests in this region. Moreover, advancements in the biotechnology sector and higher adoption rates for novel diagnostics methodologies contribute to America's cardiac marker market growth. Europe's market growth in the cardiac marker is propelled by the rising aging population, which is more prone to chronic diseases, including coronary heart disease. The availability of cutting-edge healthcare facilities, rising healthcare expenditures, and favorable regulatory policies also support the growth of the European cardiac marker market. Moreover, several key market players and ongoing research activities in the cardiac biomarkers space further stimulate market growth. The Asia-Pacific region is projected to show a significant cardiac marker market growth rate during the forecast period attributed to the large population base, the rising incidences of lifestyle diseases, and the gradual improvement in healthcare infrastructure across emerging economies.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Cardiac Marker Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

• Increasing occurrence of cardiovascular diseases
• Accessibility to a large variety of reagents and kits for cardiac biomarkers
• Improved healthcare infrastructure and spending across economies

Market Restraints

• High prices associated with cardiovascular procedures and solutions

Market Opportunities

• Ongoing advancements in cardiac markers
• Persistent improvement in the essence of point-of-care diagnostic solution

Market Challenges

• Stringent regulations and approvals for cardiac markers

Market Segmentation Analysis

• Product: Reagents and kits provide qualitative and quantitative assessment of cardiac-specific proteins
• Biomarker Type: High adoption of BNP and NT-proBNP biomarkers for diagnosing and managing heart failure
• End-User: Significant utilization of cardiac marker in laboratory testing facilities
• Indication: Potential adoption of cardiac markers in congestive heart failure situations

Market Disruption Analysis

• Porter’s Five Forces Analysis
• Value Chain & Critical Path Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Trade Analysis
• Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cardiac Marker Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cardiac Marker Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Mindray Expands Cardiac Biomarker Portfolio with Launch of New Assays

Mindray has expanded its cardiac biomarker portfolio with the introduction of new assays. These assays include troponin T, high-sensitive troponin I (hsTnI), and N-terminal pro-B type natriuretic peptide (NT-proBNP). These markers are crucial for the early diagnosis and risk stratification of various cardiovascular diseases, such as acute coronary syndrome, heart failure, sepsis, and stroke.

AUDIT MicroControls, Inc. Announces Linearity FLQ Cardiac Markers for Roche Systems

AUDIT MicroControls, Inc. partnerwed with Roche Systems of Cardiac Markers to exhibit linearity across the entire measurement range, ensuring accurate and reliable results. These systems demonstrate robust performance even in samples with complex and heterogeneous compositions.

Cipla Launches Diagnostic Device For Multiple Health Conditions

Cipla has introduced a diagnostic device that detects various health conditions, including cardiac markers such as Troponin I and Myoglobin. This point-of-care testing device delivers reliable results quickly, making it invaluable for doctors and healthcare professionals to identify a wide range of diseases, from cardiac to infectious.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cardiac Marker Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Cardiac Marker Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aehealth Limited, Becton, Dickinson and Company, BG Medicine Inc., Bio-Rad Laboratories, Inc., Biomérieux SA, Danaher Corporation, DiaSorin S.P.A., HyTest Ltd., LSI Medience Corporation, PerkinElmer Inc., QuidelOrtho Corporation, Randox Laboratories Ltd., Roche Diagnostics Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Trinity Biotech PLC.

Market Segmentation & Coverage

This research report categorizes the Cardiac Marker Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
• Instruments
• Chemiluminescence
• ELISA
• Immunochromatography
• Immunofluorescence
• Reagents & Kits
• Biomarker Type
• BNP Or NT-ProBNP
• CK-MB
• Hs-CRP
• Myoglobin
• Troponin I & T
• End-User
• Laboratory Testing Facilities
• Point of Care Testing Facilities
• Indication
• Congestive Heart Failure
• Myocardial Infarction

Region

• Americas
• Argentina
• Brazil
• Canada
• Mexico
• United States
• California
• Florida
• Illinois
• New York
• Ohio
• Pennsylvania
• Texas
• Asia-Pacific
• Australia
• China
• India
• Indonesia
• Japan
• Malaysia
• Philippines
• Singapore
• South Korea
• Taiwan
• Thailand
• Vietnam
• Europe, Middle East & Africa
• Denmark
• Egypt
• Finland
• France
• Germany
• Israel
• Italy
• Netherlands
• Nigeria
• Norway
• Poland
• Qatar
• Russia
• Saudi Arabia
• South Africa
• Spain
• Sweden
• Switzerland
• Turkey
• United Arab Emirates
• United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year